Circulating asprosin, irisin, and abdominal obesity in Chinese patients with type 2 diabetes mellitus: a case-control study

Abstract

Introduction: Studies have suggested that serum asprosin and irisin were involved in type 2 diabetes mellitus (T2DM) and obesity. This study evaluated circulating levels of asprosin and irisin and their associations with anthropometric and metabolic parameters, especially the visceral fat area (VFA) in T2DM patients with abdominal obesity (AO). Material and methods: In this case-control study, 131 patients with T2DM were grouped into an AO group (n = 68) and a non-AO group (NAO) (n = 63) based on their VFA. Anthropometric and metabolic parameters as well as serum asprosin and irisin levels were measured and compared between the 2 groups. Results: Compared to the NAO group, the AO group had significantly higher serum asprosin and irisin concentrations (3.67 ± 1.76 ng/mL vs. 2.85 ± 0.90 ng/mL, p = 0.001; 154.62 ± 61.87 pg/mL vs. 130.54 ± 34.89 pg/mL, p = 0.008, respectively) and greater VFA (p < 0.001). Serum asprosin in the AO group was positively associated with weight, waist circumference (WC), hipline, body mass index, fasting blood glucose (FBG), glycated haemoglobin (HbA1c), VFA, subcutaneous fat area, and total abdominal fat area (TAFA), and the serum irisin concentration in the AO group was positively correlated with WC, waist-to-hip ratio (WHR), VFA, and TAFA and negatively correlated with FBG. Stepwise logistic regression analysis suggested that FBG and VFA were independent factors positively associated with serum asprosin, and that FBG was independently, negatively associated with serum irisin, while VFA was independently, positively associated with serum irisin. Conclusions: Elevated serum asprosin and irisin levels in T2DM patients with AO and their correlations with other metabolic parameters suggest that both are potential therapeutic agents/targets in treating obesity and its related disorders. (Endokrynol Pol 2023; 74 (1): 55–62)